Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 49 of 94 for:    body | Recruiting, Not yet recruiting, Available Studies | "Metabolic Syndrome X"

Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome (OBEMINALE 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03692806
Recruitment Status : Recruiting
First Posted : October 2, 2018
Last Update Posted : October 4, 2018
Sponsor:
Collaborators:
Biofortis Mérieux NutriSciences
Wim Calame, Consultancy in Statistics and Experimental Design
Information provided by (Responsible Party):
LNC THERAPEUTICS

Brief Summary:
The primary objective of the study is to assess the efficacy of STABLOR® consumption on visceral fat mass compared to placebo, in persons with metabolic syndrome during 12 weeks of consumption.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Dietary Supplement: Stablor Dietary Supplement: placebo Not Applicable

Detailed Description:
It is expected that the food product STABLOR will reduce visceral fat mass in subjects with metabolic syndrome and therefore will improve cardiometabolic risk factors. The aim of the current study is to assess the impact of a 12-week intake of STABLOR, compared to a placebo, on visceral fat in patients with metabolic syndrome. The primary objective of the study is to assess the efficacy of 12-week STABLOR® consumption on visceral fat mass compared to placebo, in persons with metabolic syndrome. The Secondary outcomes include Anthropometric measurements and body composition, metabolic syndrome status, STABLOR® metabolism, Cardiovascular biomarkers, Systemic inflammation, Quality of life and Behavior.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 3-month Randomized Double Blind Placebo-controlled Multicenter Study to Assess the Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome
Actual Study Start Date : September 11, 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Stablor
2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
Dietary Supplement: Stablor
Stablor sachet

Placebo Comparator: placebo
2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
Dietary Supplement: placebo
placebo sachet




Primary Outcome Measures :
  1. Absolute change of visceral fat mass (in cubic millimeter) assessed by Magnetic Resonance Imaging [ Time Frame: between week 0, week 9, week 12 ]

Secondary Outcome Measures :
  1. Change of visceral fat mass in percentage assessed by Magnetic Resonance Imaging [ Time Frame: between Week 0, Week 9 and Week 12 ]
  2. Changes of total abdominal fat mass in cubic millimeter assessed by Magnetic Resonance Imaging [ Time Frame: between Week 0, Week 9 and Week 12 ]
  3. Changes of subcutaneous fat mass in cubic millimeter assessed by Magnetic Resonance Imaging [ Time Frame: between Week 0, Week 9 and Week 12 ]
  4. Changes of total abdominal fat mass in percentage assessed by Magnetic Resonance Imaging [ Time Frame: between Week 0, Week 9 and Week 12 ]
  5. Changes of subcutaneous fat mass in percentage assessed by Magnetic Resonance Imaging [ Time Frame: between Week 0, Week 9 and Week 12 ]
  6. Changes of body fat mass measured by Dual-energy X-ray absorptiometry [ Time Frame: between Week 0 and Week 12 ]
  7. Changes of body lean mass measured by Dual-energy X-ray absorptiometry [ Time Frame: between Week 0 and Week 12 ]
  8. Changes of trunk fat assessed by Dual-energy X-ray absorptiometry [ Time Frame: between Week 0 and Week 12 ]
    calculated trunk fat

  9. Changes of anthropometrics measurements : weight [ Time Frame: between Week 0 and Week 12 ]
    Weight

  10. Changes of anthropometrics measurements : BMI [ Time Frame: between Week 0 and Week 12 ]
    BMI

  11. Changes of anthropometrics measurements: Waist circumference [ Time Frame: between Week 0 and Week 12 ]
    Waist Circumference

  12. Changes of anthropometrics measurements: Hip Circumference [ Time Frame: between Week 0 and Week 12 ]
    Hip Circumference

  13. Changes of anthropometrics measurements: Waist to Hip ratio [ Time Frame: between Week 0 and Week 12 ]
    Waist to Hip ratio

  14. Changes of anthropometrics measurements: Waist to Height ratio [ Time Frame: between Week 0 and Week 12 ]
    Waist to Height ratio



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female or male
  • Age between 18 and 65 years (limits included),
  • BMI between 27 and 40 kg/m² (limits included),
  • With metabolic syndrome: Waist circumference > 94 cm for male (>90 cm for male of South-East Asian, Chinese and Japanese ethnic groups) and > 80 cm for female and at least two of the following criteria :

    • Triglycerides levels ≥ 1.5 g/L (1.71 mmol/L) or stable under treatment for at least 6 months,
    • HDL cholesterol levels <0.40 g/L (1.03 mmol/L) for male and <0.5 g/l (1.29 mmol/L) for female or stable under treatment for at least 6 months,
    • Fasting plasma glucose ≥1 g/L (5.6 mmol/L) and non-diabetic,
    • Blood pressure ≥130 mmHg (systolic) and/or 85 mmHg (diastolic) or stable under antihypertensive treatment for at least 6 months,
  • Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination,
  • Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form,

Exclusion Criteria:

  • Suffering from a metabolic disorder such as diabetes uncontrolled thyroidal trouble or other metabolic disorder,
  • Suffering from a cardiac insufficiency, inflammatory disease, severe hepatic of renal insufficiency, or gastrointestinal disorders (Crohn's disease or Ulcerative Colitis) or others diseases found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease),
  • Having suffered of stroke or ictus within the last 6 months,
  • Suffering of depression,
  • Had a major surgical procedure within the last 6 months,
  • Had a bariatric surgery,
  • With a known or suspected food allergy or intolerance to lactose or soja, or hypersensitivity to any of the study products' ingredient,
  • Who does not like the investigational product flavors "vanilla-toffee", "chocolate" and "coffee",
  • Having a biological selection profile considered as abnormal by the investigator (BUN, Creatinine, calcium, Liver enzymes (GGT, AST, ALT), Blood Cell Count, , HIV, HCV, lipids (TG, HDL, LDL, total cholesterol),glycaemia, B HCG),
  • Pregnant (positive pregnancy test at selection visit) or lactating women or intending to become pregnant within 6 months ahead,
  • Women of child bearing potential without efficient contraception,
  • Under nutritional supplement or drugs acting on weight or satiety according to the investigator or stopped less than 6 months before the study,
  • With a current or planned in the next 6 months specific diet (hypocaloric, vegan, vegetarian…) or stopped less than 6 months before the study,
  • Treated with drugs acting on visceral fat mass &inflammation : corticosteroids, neuroleptics, alpha et beta blockers, anti-HIV tritherapy, anti-TNF alpha, antidepressant or anticoagulating agents,
  • Treated with antibiotics in the 3 months prior to selection,
  • With significant change in food habits or in physical activity in the 6 months before the V0 visit,
  • With significant changes in lipid abnormality of antihypertensive treatment within 3 months prior to selection,
  • With a personal history of bulimia or significant eating disorders according to the investigator,
  • Consuming more than 3 standard drinks of alcoholic beverage daily for men or 2 daily for women or not agreeing to keep his alcohol consumption habits unchanged throughout the study,
  • Consuming tobacco,
  • Consuming drugs,
  • Patients who suffer from claustrophobia,
  • Patients who have contraindications to perform an MRI such as pacemakers, intracranial clips incompatible with MRI, heart valves, hearing aid,... and other types of implants incompatible with MRI,
  • Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,
  • Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,
  • Presenting a psychological or linguistic incapability to sign the informed consent,
  • Impossible to contact in case of emergency.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03692806


Contacts
Layout table for location contacts
Contact: Laure Anne Serres +33240205799 laure-anne.serres@mxns.com
Contact: Valérie Collet +33240205799 valerie.collet@mxns.com

Locations
Layout table for location information
France
Biofortis Recruiting
Saint Herblain, France, 44800
Contact: Biofortis    +33240205799      
Sponsors and Collaborators
LNC THERAPEUTICS
Biofortis Mérieux NutriSciences
Wim Calame, Consultancy in Statistics and Experimental Design
Investigators
Layout table for investigator information
Principal Investigator: David Gendre, MD BioFortis
Principal Investigator: Francois-André ALLAERT CEN Experimental
Principal Investigator: Yves DONAZZOLO Eurofins Optimed

Layout table for additonal information
Responsible Party: LNC THERAPEUTICS
ClinicalTrials.gov Identifier: NCT03692806     History of Changes
Other Study ID Numbers: 2018-A01402-53
First Posted: October 2, 2018    Key Record Dates
Last Update Posted: October 4, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Metabolic Syndrome
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases